These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 16857802)

  • 1. A phase I clinical and pharmacokinetic study of oral CI-1033 in combination with docetaxel in patients with advanced solid tumors.
    Garland LL; Hidalgo M; Mendelson DS; Ryan DP; Arun BK; Lovalvo JL; Eiseman IA; Olson SC; Lenehan PF; Eder JP
    Clin Cancer Res; 2006 Jul; 12(14 Pt 1):4274-82. PubMed ID: 16857802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I and pharmacokinetic study of weekly docetaxel, cisplatin, and daily capecitabine in patients with advanced solid tumors.
    Fakih MG; Creaven PJ; Ramnath N; Trump D; Javle M; Strychor S; Repinski TV; Zamboni BA; Schwarz JK; French RA; Zamboni WC
    Clin Cancer Res; 2005 Aug; 11(16):5942-9. PubMed ID: 16115937
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I and pharmacokinetic study of docetaxel administered in combination with continuous intravenous infusion of 5-fluorouracil in patients with advanced solid tumors.
    Van Den Neste E; de Valeriola D; Kerger J; Bleiberg H; Kusenda Z; Brassinne C; Bartholomeus S; Selleslags J; Hennebert P; Wythouck H; Cazenave I; Lefresne-Soulas F; Piccart M
    Clin Cancer Res; 2000 Jan; 6(1):64-71. PubMed ID: 10656433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I combining a P-glycoprotein inhibitor, MS209, in combination with docetaxel in patients with advanced malignancies.
    Diéras V; Bonneterre J; Laurence V; Degardin M; Pierga JY; Bonneterre ME; Marreaud S; Lacombe D; Fumoleau P
    Clin Cancer Res; 2005 Sep; 11(17):6256-60. PubMed ID: 16144929
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I study of combination therapy with S-1 and docetaxel (TXT) for advanced or recurrent gastric cancer.
    Yoshida K; Hirabayashi N; Takiyama W; Ninomiya M; Takakura N; Sakamoto J; Nishiyama M; Toge T
    Anticancer Res; 2004; 24(3b):1843-51. PubMed ID: 15274365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I and pharmacokinetic study of lapatinib and docetaxel in patients with advanced cancer.
    LoRusso PM; Jones SF; Koch KM; Arya N; Fleming RA; Loftiss J; Pandite L; Gadgeel S; Weber BL; Burris HA
    J Clin Oncol; 2008 Jun; 26(18):3051-6. PubMed ID: 18565892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I study of docetaxel in combination with the P-glycoprotein inhibitor, zosuquidar, in resistant malignancies.
    Fracasso PM; Goldstein LJ; de Alwis DP; Rader JS; Arquette MA; Goodner SA; Wright LP; Fears CL; Gazak RJ; Andre VA; Burgess MF; Slapak CA; Schellens JH
    Clin Cancer Res; 2004 Nov; 10(21):7220-8. PubMed ID: 15534095
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I safety and pharmacokinetic study of SU-014813 in combination with docetaxel in patients with advanced solid tumours.
    de Jonge MJ; Dumez H; Kitzen JJ; Beuselinck B; Verweij J; Courtney R; Battista A; Brega N; Schöffski P
    Eur J Cancer; 2011 Jun; 47(9):1328-35. PubMed ID: 21439816
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I and pharmacokinetic trial of erlotinib in combination with weekly docetaxel in patients with taxane-naive malignancies.
    Chiorean EG; Porter JM; Foster AE; Al Omari AS; Yoder CA; Fife KL; Strother RM; Murry DJ; Yu M; Jones DR; Sweeney CJ
    Clin Cancer Res; 2008 Feb; 14(4):1131-7. PubMed ID: 18281547
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I study of bi-weekly docetaxel for recurrent or advanced gastric cancer patients whose disease progressed by prior chemotherapy.
    Kimura Y; Yano H; Taniguchi H; Iwazawa T; Danno K; Kagara N; Kanoh T; Ohnishi T; Tono T; Nakano Y; Monden T; Imaoka S
    Jpn J Clin Oncol; 2011 Jun; 41(6):747-51. PubMed ID: 21498408
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I and pharmacokinetic study of exisulind and docetaxel in patients with advanced solid tumors.
    Witta SE; Gustafson DL; Pierson AS; Menter A; Holden SN; Basche M; Persky M; O'Bryant CL; Zeng C; Baron A; Long ME; Gibbs A; Kelly K; Bunn PA; Chan DC; Pallansch P; Eckhardt SG
    Clin Cancer Res; 2004 Nov; 10(21):7229-37. PubMed ID: 15534096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Docetaxel and ifosfamide in patients with advanced solid tumors: results of a phase I study.
    Pronk LC; Schrijvers D; Schellens JH; de Bruijn EA; Planting AS; Locci-Tonelli D; Groult V; Verweij J; van Oosterom AT
    Semin Oncol; 1998 Feb; 25(1 Suppl 2):23-8. PubMed ID: 9535208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I dose-escalation trial of 2-deoxy-D-glucose alone or combined with docetaxel in patients with advanced solid tumors.
    Raez LE; Papadopoulos K; Ricart AD; Chiorean EG; Dipaola RS; Stein MN; Rocha Lima CM; Schlesselman JJ; Tolba K; Langmuir VK; Kroll S; Jung DT; Kurtoglu M; Rosenblatt J; Lampidis TJ
    Cancer Chemother Pharmacol; 2013 Feb; 71(2):523-30. PubMed ID: 23228990
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase-I dose escalation and sequencing study of docetaxel and continuous infusion topotecan in patients with advanced malignancies.
    Posey JA; Wang H; Hamilton J; Delgrosso A; Zhang R; Freda T; Zamboni WC
    Cancer Chemother Pharmacol; 2005 Aug; 56(2):182-8. PubMed ID: 15838660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I dose escalation study of weekly docetaxel and carboplatin in elderly patients with nonsmall cell lung cancer.
    Kaira K; Tsuchiya S; Sunaga N; Yanagitani N; Watanabe S; Imai H; Hisada T; Ishizuka T; Saito R; Mori M
    Am J Clin Oncol; 2007 Feb; 30(1):51-6. PubMed ID: 17278895
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased bioavailability of intravenous versus oral CI-1033, a pan erbB tyrosine kinase inhibitor: results of a phase I pharmacokinetic study.
    Simon GR; Garrett CR; Olson SC; Langevin M; Eiseman IA; Mahany JJ; Williams CC; Lush R; Daud A; Munster P; Chiappori A; Fishman M; Bepler G; Lenehan PF; Sullivan DM
    Clin Cancer Res; 2006 Aug; 12(15):4645-51. PubMed ID: 16899614
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Docetaxel, ifosfamide and cisplatin in solid tumour treatment: a phase I study.
    Specenier P; Rasschaert M; Van den Brande J; Dyck J; Schrijvers D; Huizing MT; Vermorken JB
    Anticancer Drugs; 2010 Mar; 21(3):306-12. PubMed ID: 20087171
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I dose-escalation study of intravenous aflibercept in combination with docetaxel in patients with advanced solid tumors.
    Isambert N; Freyer G; Zanetta S; You B; Fumoleau P; Falandry C; Favier L; Assadourian S; Soussan-Lazard K; Ziti-Ljajic S; Trillet-Lenoir V
    Clin Cancer Res; 2012 Mar; 18(6):1743-50. PubMed ID: 22261804
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I trial to investigate the safety, pharmacokinetics and efficacy of sorafenib combined with docetaxel in patients with advanced refractory solid tumours.
    Awada A; Hendlisz A; Christensen O; Lathia CD; Bartholomeus S; Lebrun F; de Valeriola D; Brendel E; Radtke M; Delaunoit T; Piccart-Gebhart M; Gil T
    Eur J Cancer; 2012 Mar; 48(4):465-74. PubMed ID: 22285181
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I trial of bortezomib in combination with docetaxel in patients with advanced solid tumors.
    Messersmith WA; Baker SD; Lassiter L; Sullivan RA; Dinh K; Almuete VI; Wright JJ; Donehower RC; Carducci MA; Armstrong DK
    Clin Cancer Res; 2006 Feb; 12(4):1270-5. PubMed ID: 16489083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.